Monthly Archives: May 2015

New screening method for prostate cancer recurrence

The American Cancer Society estimated that 220,800 new cases of prostate cancer will be diagnosed in the United States in 2015. Approximately 27,540 men will die of the disease, accounting for 5 percent of all cancer deaths. A common treatment … Continue reading

Posted in Research | Tagged , , | Leave a comment

Cancer survivors have evolving information needs

Cancer patient’s information needs appear to differ depending on the type of cancer they have and where they are in their survivorship. Clinicians caring for cancer survivors may need to understand these needs in order to better address survivor’s concerns … Continue reading

Posted in Research | Tagged , , | Leave a comment

Body’s ‘serial killers’ captured on film destroying cancer cells

A dramatic video has captured the behaviour of cytotoxic T cells – the body’s ‘serial killers’ – as they hunt down and eliminate cancer cells before moving on to their next target. In a study published today in the journal Immunity, … Continue reading

Posted in Research | Tagged , , | Leave a comment

Nuclear medicine scan could identify who might benefit from aromatase inhibitor treatment

A new, noninvasive nuclear medicine test can be used to determine whether aromatase inhibitor treatment will be effective for specific cancer patients, according to a recent study reported in The Journal of Nuclear Medicine. The research shows that a PET scan … Continue reading

Posted in Uncategorized | Tagged , | Leave a comment

Potential for a more personalized approach to womb cancer

Traditionally, patients with endometrial cancer, cancer of the womb lining,  have their disease risk classified using a combination of clinical and tissue characteristics, including their age and the growth and invasion of their tumour. Around 15-20% of patients have high-risk … Continue reading

Posted in Research | Tagged , , | Leave a comment

Statin drugs can delay prostate cancer progression in patients

Men who went on cholesterol-lowering statin drugs when they began androgen deprivation therapy for prostate cancer had a longer time in which their disease was under control than did men who didn’t take statins, a clinical trial led by Dana-Farber … Continue reading

Posted in Research | Tagged , , | Leave a comment